Therefore, not only was this policy safe, but it simplified patient management in all cases, as it obviated the need to treat steroid-related complications [e.g., hyperglycemia with finger stick glucose monitoring and sliding scale insulin (Al-Shoumer et al., 1995; Rajaratnam et al., 2003), and gastric ulcers with pharmacologic gastric protectors, typically proton pump inhibitors] or to wean exogenous steroids. The gene discussed is INS; the disease is gastric ulcer.